Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hee Jeong | - |
dc.contributor.author | Lee, Haekyung | - |
dc.contributor.author | Oh, Song Hee | - |
dc.contributor.author | Park, Suyeon | - |
dc.contributor.author | Jung, Kwang-Young | - |
dc.contributor.author | Kim, Hyoungnae | - |
dc.contributor.author | Kwon, Soon Hyo | - |
dc.contributor.author | Jeon, Jin Seok | - |
dc.contributor.author | Han, Dong Cheol | - |
dc.contributor.author | Noh, Hyunjin | - |
dc.date.accessioned | 2021-08-11T09:24:50Z | - |
dc.date.available | 2021-08-11T09:24:50Z | - |
dc.date.issued | 2019-08 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4331 | - |
dc.description.abstract | Beta2-adrenergic receptor (beta 2AR) agonists can have protective effects targeting macrophage activation, but research on human subjects has not been done. This study was designed to assess the relationship between the use of beta 2AR agonists and diabetic vascular complications. Using data from the Korean National Health Insurance Service, adults first diagnosed with diabetes in 2004 (n = 249,222) were followed up until 31 December 2015. Propensity score matching was performed between case and control groups (n = 5179 in each), and multivariate analysis was conducted. The beta 2AR agonist group was divided into quartiles according to the duration of beta 2AR agonist use. During the follow-up, the incidence of vascular complications gradually decreased as the duration of beta 2AR agonist administration increased. Multivariate analysis revealed that the hazard ratio for all composite vascular complications was 0.80 (95% CI, 0.75-0.86, p < 0.001) in the longest quartile of beta 2AR agonist use as compared with the control group after adjusting for confounding variables. The association between the duration of beta 2AR agonist use and the risk of each vascular complication including cerebrovascular, peripheral vascular, peripheral neural, renal, and ophthalmic complications was consistent, and the risks were significantly lower in the longest users than the control group. Long-term use of beta 2AR agonists may exert a protective effect against diabetic vascular complications. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Association between Beta2-Adrenergic Receptor Agonists and the Risk of Vascular Complications in Diabetic Patients: A Population-Based Cohort Study | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/jcm8081145 | - |
dc.identifier.wosid | 000483737700070 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Medicine, v.8, no.8 | - |
dc.citation.title | Journal of Clinical Medicine | - |
dc.citation.volume | 8 | - |
dc.citation.number | 8 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | PERIPHERAL NEUROPATHY | - |
dc.subject.keywordPlus | SOUTH-KOREA | - |
dc.subject.keywordPlus | NEPHROPATHY | - |
dc.subject.keywordPlus | COPD | - |
dc.subject.keywordAuthor | diabetes | - |
dc.subject.keywordAuthor | vascular complications | - |
dc.subject.keywordAuthor | beta2-adrenergic receptor | - |
dc.subject.keywordAuthor | macrophages | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.